Pancreatic beta-cell glucose-sensing and hormone secretion machinery (GSIS machinery)

The pancreatic beta-cell glucose-sensing and hormone secretion machinery is a multi-step physiological system that regulates insulin release in response to blood glucose levels. This process, known as glucose-stimulated insulin secretion (GSIS), involves glucose uptake, metabolic sensing by glucokinase, and the closure of ATP-sensitive potassium (KATP) channels (Matschinsky & Wilson, 2019). The resulting membrane depolarization opens voltage-gated calcium channels, leading to an influx of calcium that triggers the exocytosis of insulin granules (Ashcroft & Rorsman, 2012). This machinery is critical for maintaining glucose homeostasis, and its dysfunction is a primary driver of Type 2 diabetes and hyperinsulinemic hypoglycemia (Rorsman & Braun, 2013). Therapeutic strategies target various components of this system, such as KATP channels with sulfonylureas or glucokinase with small-molecule activators, to correct insulin secretion defects (Campbell & Newgard, 2021).

Other names

Glucose-stimulated insulin secretion pathwayGSIS machineryBeta-cell stimulus-secretion couplingPancreatic beta-cell glucose-sensing apparatus

The machinery couples glucose metabolism to insulin release via the ATP-mediated closure of KATP channels and subsequent calcium-triggered exocytosis (Ashcroft & Rorsman, 2012). Drugs like sulfonylureas directly close KATP channels, while glucokinase activators lower the threshold for glucose-stimulated secretion (Matschinsky & Wilson, 2019). Incretin-based therapies further modulate this machinery by enhancing cAMP-dependent signaling pathways that potentiate the secretory response (Campbell & Newgard, 2021).